Analyst Upgrades: Tesla, JPMorgan Chase, Imprivata

Analysts upwardly revised their ratings on Tesla Motors Inc (TSLA), JPMorgan Chase & Co. (JPM), and Imprivata Inc (IMPR)

Aug 17, 2015 at 9:18 AM
facebook twitter linkedin

Analysts are weighing in today on Model S maker Tesla Motors Inc (NASDAQ:TSLA), financial force JPMorgan Chase & Co. (NYSE:JPM), and healthcare tech firm Imprivata Inc (NYSE:IMPR). Here's a quick roundup of today's bullish brokerage notes on TSLA, JPM, and IMPR.

  • TSLA is sizzling in pre-market trading, after Morgan Stanley boosted its price target to $465 from $280 -- in never-before-seen territory -- citing the company's "potential to lead the revolution in shared mobility and more confidence around the commercial viability of Tesla Energy." Specifically, the shares are pointed 5.2% higher. On the charts, the stock has been consolidating in the $235-$245 range, after touching its most recent high of $286.65 late last month -- closing at $243.15 on Friday. Today's expected bounce could spook Tesla Motors Inc short sellers. Nearly one-quarter of the equity's float is sold short, representing about seven days' worth of pent-up buying power, at typical volumes. Last week, TSLA made headlines by announcing a $642 million secondary offering.

  • KBW upgraded its rating on JPM to "outperform" from "market perform," rewarding a stock that's advanced 8.5% year-to-date. On Friday, the shares settled at $67.89, just above their 80-day moving average. The bullish note is par for the course, as far as analysts are concerned. In fact, two-thirds of brokerages have doled out "buy" or better assessments toward JPMorgan Chase & Co. However, traders at the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) are more skeptical. During the last two weeks, 1.14 JPM puts have been bought to open for every call -- a ratio that outstrips 90% of comparable readings from the last year.

  • IMPR is being showered with positive analyst attention. Overnight, Barclays, J.P. Morgan Securities, and Stifel each either started or resumed coverage on the stock with the equivalent of a "buy" rating. Also, Barclays doled out a $28 price target, while the other two brokerages handed down $24 targets -- all significantly higher than Friday's close at $18.72, and well above last Thursday's all-time peak of $19.64. Taking a step back, 100% of covering analysts currently consider Imprivata Inc a "strong buy." It's no wonder, either -- IMPR has been a technical marvel, advancing 44% year-to-date.

Get the skinny on all the biggest stories of the morning… Sign up now to get Schaeffer's Midday Market Check delivered straight to your inbox!


Stop leaving money on the table with the same old broken options trading approach...

There is no options strategy that more perfectly capitalizes during earnings season better than this simple call and put buying strategy. Perfect for aggressive traders looking to recover their suffering portfolios so far in 2022. With the simplest possible options strategy, Schaeffer's team with 100+ years of options trading excellence, target 200% gains on every single trade. So many trades are being beaten down by the market, but don't be one of them! Don't waste another second... join us right now before the next trade is released! 

Schaeffer's Daily Bulletin Offer


Special Offers from Schaeffer's Trading Partners